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Abstract
Objective: Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin
(PLD). Unfortunately, most patients do not benefit from treatment. Prediction of response is crucial to optimize PLD
use and avoid unnecessary toxicities. We aimed at assessing the value of topoisomerase II alpha (TOP2A) expression
as predictive marker of response to PLD-based therapy in patients with relapsed EOCs.
Methods: We retrospectively analyzed Formalin Fixed Paraffin Embedded (FFPE) tissues from 101 patients with
platinum resistant (PR) or partially platinum-sensitive (PPS) EOCs treated with PLD-based chemotherapy beyond
second line in three referral cancer centers between January 2010 and June 2018. TOP2A expression was measured
by immunohistochemistry (IHC): images of each sample were acquired by optical microscope and analyzed by
using automatic counter software. Correlation between TOP2A expression and response to PLD was assessed. Since
no cut-off for positivity has been validated yet, we dichotomized TOP2A expression based on a cut-off of 18%
(mean value in this study).
Results: TOP2A expression beyond cut-off was not prognostic for primary platinum-free interval in our series (p = 0.77)
neither for optimal cytoreduction (p = 0.9). TOP2A > 18% was associated with a longer time to progression (TTP)
following PLD-treatment, although not statistically significant (p = 0.394). No difference was observed between PR and
PPS patients’ groups (p = 0.445 and p = 0.185, respectively). Not unexpectedly, patients with TOP2A expression > 18%
treated with PLD monotherapy achieved a longer TTP compared with PLD-doublet therapy (p = 0.05).
Conclusions: Our data suggest that TOP2A status might predict activity of PLD in patients with PR/PPS EOCs.
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Introduction
Epithelial ovarian cancer (EOC) is the leading cause of
death among women with gynecological malignancies
with 22,400 estimated new cases in 2017 [1]. Optimal
cytoreduction to no residual disease followed by adju-
vant chemotherapy with platinum-taxane combination is
the standard of care [2, 3]. However, over 70% of pa-
tients with advanced stage diseases experience relapse
after front-line treatment [4]. Residual disease (R) at pri-
mary surgery and sensitivity to first-line platinum-based
chemotherapy (PFI, platinum-free interval) still repre-
sent the major determinants of clinical outcome [5, 6].
For partially platinum-sensitive patients (PPS), defined
as progressed between six and twelve months after con-
clusion of first line platinum-therapy, standard options
include a second line platinum-based-doublet chemo-
therapy or pegylated liposomal doxorubicin [PLD] - tra-
bectedin. For platinum resistant ovarian cancers (PR),
defined as progressing within 6 months from last plat-
inum therapy, limited and debatable options are avail-
able [7]. In these patients, subsequent single-agent
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chemotherapies with non-platinum drugs show limited
activity [8]. The most effective drugs include paclitaxel,
gemcitabine, etoposide, topotecan and PLD [9–12].
PLD is one of the preferred drugs due to its favorable
toxicity profile (absence of alopecia, limited cardiac tox-
icity, and only moderate hematological and skin toxicity)
[13, 14]. However, response rates range from 16 to 25%.
Consequently, to optimize the use of PLD and avoid un-
necessary toxicities, prediction of response is crucial.
TOP2A gene is located on the locus q21 of chromo-
some 17, close to the HER2 gene, and is responsible for
coding the nuclear enzyme type 2 topoisomerase alpha
(TOP2A) [15]. TOP2A plays a key role in DNA stability
and represents one of the targets of chemotherapeutic
agents, such as etoposide and anthracyclines [16–18].
Several retrospective analyses have already suggested a
correlation between TOP2A status and response to
anthracyclines in breast cancer, both as neoadjuvant and
adjuvant treatment [19–23]. Conversely, in EOCs few
studies have investigated the prognostic and predictive
role of TOP2A. Heterogeneous results are mainly related
with the use of different detection techniques such as
immunohistochemistry (IHC), Real-Time Polymerase
Chain Reaction (RT-PCR) and Fluorescent-In Situ
Hybridization (FISH) [24–26].
The aim of our study was to assess the correlation be-
tween TOP2A protein expression and clinical outcome
of patients following PLD-based treatment in both plat-
inum partially-sensitive and platinum-resistant patients.
Materials and methods
Patients’ characteristics
We screened a total of 128 patients with PR/PPS EOCs
treated with PLD-based chemotherapy beyond second
line in three different referral centers (Candiolo Cancer
Institute FPO/IRCCS, Ordine Mauriziano Hospital and
Sant’Anna Hospital) between January 2010 and April
2018. Among these, 27 cases were excluded due to
non-complete medical records or unavailability of tumor
material for IHC analysis. For each of the 101 selected
patients, the following clinico-histopathological data
were recorded: i) age at diagnosis; ii) morphological fea-
tures of ovarian cancer including tumor histotype, grade
(according to World Health Organization Classification
of Tumours of Female Reproductive Organs, 4th Edi-
tion) and stage (according to the International Feder-
ation of Gynecology and Obstetrics [FIGO]); iii) PFI
(Platinum-Free Interval) to last platinum-based therapy;
iv) number of previous lines before PLD; v) PLD-based
treatment scheme; vi): Cancer Antigen 125 (CA-125)
pre- and post-PLD treatment; vii) best radiological re-
sponse according to RECIST 1.1 criteria, if available; viii)
BRCA status; ix) date of death or last follow up (FU).
Complete patients’ clinical data are reported in Table 1.
Table 1 Patients’ characteristics
Patient number 101
Median age (years) 60
Histological subtype
Serous 79 (78, 3%)
Endometrioid 7 (7%)
Mucinous 2 (1, 9%)
Clear cell 2 (1, 9%)
Mixed 3 (2, 9%)






IC 1 (0, 9%)
IIA 4 (3, 9%)
IIB 7 (7%)
IIIA 4 (3, 9%)
IIIB 8 (8%)
IIIC 56 (55, 5%)
IV 21 (20, 8%)
PFI
< 6 months 65 (64, 4%)
≥ 6 months 36 (35, 6%)
Number of previous chemoterapies
1 82 (87, 3%)
2 10 (10, 6%)
≥ 3 2 (2, 1%)
PLD-based regimen
PLD monotherapy 54 (53, 4%)
Carbo-PLD 30 (29, 7%)
Trabe-PLD 17 (16, 9%)




BRCA 1–2 mutation 11 (10, 9%)
BRCA 1–2 wild-type 12 (11, 9%)
VUS/HRD 6 (5, 9%)
Unknown 72 (71, 3%)
FIGO International Federation of Gynaecology and Obstretics, PFI Platinum
Free Interval from first platinum-based therapy, PLD Pegylated Liposomal
Doxorubicin, Carbo Carboplatin, Trabe Trabectidin, CA-125 Cancer Antigen 125
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IRB approval
In Italy, the National Regulation established that retro-
spective studies require a notification to the local ethical
committee with the tacit consent formula. We therefore
notified the Candiolo Cancer Institute ethical committee
about the conduct of the study on August 2016. All pa-
tients included in our retrospective study were treated
according with the ethical standards of our local com-
mittee on human experimentation and with the Helsinki
Declaration.
Immunoistochemistry
FFPE tissue blocks of the above 101 cases were obtained
from the archives of the Units of Pathology at Candiolo
Cancer Institute (IRCCS), A.S.O. Ordine Mauriziano
Hospital and Sant’Anna Hospital at Torino. Immunohis-
tochemistry was performed as previously described [27]
to detect topoisomerase II alpha using a monoclonal
rabbit antibody (clone D10G9 Cell Signaling Technol-
ogy). At least 10 images of each sample were acquired
by optical microscope (20×) connected with
charge-coupled device (CCD) camera and analyzed by
using automatic counter software (NIH ImageJ). Only
cells with TOP2A nuclear signatures were considered as
positive. TOP2A expression was calculated as the ratio
between positive cells and a total of at least 500 cells in
10 different fields.
Statistical analysis
Time to progression (TTP) following PLD-based treat-
ment was assessed as the time elapsed between PLD
start and first tumor progression or death, whichever
comes first. TTP was estimated by the Kaplan-Meier
method and compared according to TOP2A expression
using the log-rank test. Because no positivity cut-off has
been validated, similar to other studies we dichotomized
TOP2A expression based on the mean value of our co-
hort (18%). A p < 0.05 was considered statistically signifi-
cant. All analyses were performed using the SPSS
statistical software program, version 22.0 (IBM SPSS
Inc., Chicago, IL, United States of America).
Results
In our series, more than 75% were serous high grade,
G3, advanced stage (IIIC-IV) EOCs. PFI showed that al-
most 65% of the patients were platinum-resistant.
Eighty-seven per cent of the patients received PLD as
second-line therapy and more than 50% as single-agent.
All 101 cases analyzed showed nuclear TOP2A expres-
sion, which ranged from 2 to 48% of nuclear cell signa-
ture with a mean of 18% (Fig. 1).
No statistically significant association between TOP2A
expression and tumor histotype, grading or PFI were
found. TOP2A expression beyond cut-off was not prog-
nostic for primary platinum-free interval in our series
(p = 0.77) neither for optimal cytoreduction (p = 0.9).
Fig. 1 TOP2A expression detected at IHC (images acquired by optical microscope 20×). a, b TOP2A over-expression above cut-off of 18% nuclear
cells signature versus. c, d TOP2A expression below cut-off
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Median time to progression from PLD-based treat-
ment was 5, 1 months (range 1–24months). Cancer
Antigen 125 (CA-125) was above normal range in the
93% of cases before PLD treatment (median value 1142
UI/dL) and in the 78, 3% post-treatment (median value
1493 UI/dL), but not statistical correlation was found
between serological response and TOP2A status (p =
0.285). TOP2A expression beyond cut-off was associated
with a higher probability of response to PLD in terms of
TTP, although not statistically significant (p = 0.0394,
Fig. 2a). No difference was observed between PR and
PPS groups (p = 0.445 and p = 0.185, respectively).
Among the 67 patients with available radiological assess-
ments, no difference could be observed in term of re-
sponse: 31 patients obtained a disease control (partial
response [PR] + stable disease [SD]) and 36 progressed.
Patients with TOP2A higher expression treated with
PLD monotherapy achieved a longer TTP compared
with PLD-doublet therapy (5, 8 vs 3, 4 months, p =
0.035, Fig. 2b). Complete results are summarized in
Table 2.
BRCA germline-status was known in 29 patients.
Among the eleven mutated patients, 7 carried a BRCA1
and 4 a BRCA2 mutations; twelve patients were wild-type
and other six patients showed a variant of unknown sig-
nificance (VUS). As expected, patients with BRCA muta-
tions achieved a longer TTP (median 11months, range 3–
22, data not shown) compared with the median of our
study population, although statistical analysis could not be
performed due to the small numbers of cases.
Fig. 2 Correlation between TOP2A expression and PLD-Treatment Free Interval. a Cases showing TOP2A expression above 18% (mean value of
this study) versus cases with TOP2A below cut-off limit. b Patients with TOP2A expression above 18% treated with PLD-monotherapy versus
PLD-based polychemotherapy
Table 2 Correlation between TOP2A expression and response to Pegylated Lyposomal Doxorubicin (PLD) in terms of time to
progression (TTP)
Time To Progression (TTP) to PLD TOP2A < 18% TOP2A≥ 18% p-value
All patients, months (CI 95%) 4,5 (3,1-5,9) 6,7 (4,8-8,6) 0,085
TTP according to Platinum Free Interval
PR 3,7 (2,6-4,9) 4,9 (2,9-6,9) 0,445
PPS 5,6 (2,7-8,6) 9,1 (5,8-12,4) 0,185
TTP according to chemoterapeutic regimen
PLD monotherapy 3,4 (2,5-4,3) 5,8 (3,7-3,9) 0,035
Carboplatin-PLD 8,0 (3,5-12,4) 9,6 (5,7-13,5) 0,796
PLD-Trabectidin 1,8 (0,6-3,2) 3,5 (0,6-6,3) 0,358
TTP time to progression, CI confidence interval, PR Platinum-resistant patients, PPS partially platinum-sensitive patients
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Discussion
Treatment of patients affected by relapsed PR or PPS
EOCs is still a major challenge for gynecologic oncolo-
gists and medical oncologists. To personalize the use
of PLD and avoid unnecessary toxicities, prediction of
response is of crucial importance. We have already
demonstrated that TOP2A gene copy number is asso-
ciated with protein overexpression and correlates with
the activity of PLD in a small series of 38 PR EOCs
and patients-derived xenografts (PDXs) [28]. Consider-
ing the concordance between TOP2A gene copy num-
ber and TOP2A protein expression, we aimed at
developing a cost-effective and reproducible method
(IHC) to assess the correlation between TOP2A and
PLD activity. In our study we found that the preva-
lence of TOP2A expression is consistent with that ob-
served by van der Zee at al [29]. and Faggad et al. [26]
in their retrospective series. Moreover, we report here
that TOP2A expression above 18% is associated with a
higher probability of response to PLD in patients with
PR/PPS EOCs. Finally, we showed that, regardless
platinum-free interval, patients with TOP2A expres-
sion above cut-off, achieved a longer time to progres-
sion if treated with PLD monotherapy compared with
PLD-doublet therapy (p = 0.035). These data may be
explained by the known detrimental effect of
poly-chemotherapy in pretreated patients [30, 31].
To our knowledge this is the biggest study investigat-
ing the role of TOP2A in predicting PLD activity in
ovarian cancers.
However, our study has several limits. First of all
the absence of a validated cut-off for TOP2A positiv-
ity at IHC impairs the reproducibility of the test.
Moreover, assessment of TOP2A expression mainly at
diagnosis may be discordant with TOP2A status at re-
lapse, considering tumor heterogeneity and clonal
evolution during progression. Finally our patient
population was heterogeneous in terms of PFIs and
PLD combinations.
Other predictors of sensitivity to anthracyclines have
been studied. Among these, chromosome 17 polysomy,
HER2, TIMP-1 [32], stroma-related genes and the im-
mune response [33] have been already investigated with
controversial results. More recently, defects in the hom-
ologous recombination system, such as BRCA1 and
BRCA2 mutations have been associated with higher
rates of response to platinum-based and anthracyclines
regimens both in triple negative breast cancers (TNBCs)
and EOCs [34].
In conclusion, although we believe that these results
should be regarded as an hypothesis-generating attempt
to identify a biomarker of response, only a multifactorial
panel could be predictive of response to PLD in ovarian
cancer [35].
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